How do you take PERJETA?
PERJETA is given as an intravenous (IV) infusion, which means that medication is administered directly and slowly into the bloodstream through a vein.
How long is PERJETA given?
PERJETA is given every 3 weeks as an IV infusion PERJETA and Herceptin® (trastuzumab) are given back-to-back at the same visit. You will also get chemotherapy as part of your treatment, but it may be on a different schedule. *Unless side effects become too difficult to manage, or the cancer comes back sooner.
What are NCCN Guidelines?
The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions that currently apply to 97 percent of cancers affecting patients in the United States.
Who is eligible for PERJETA?
Neoadjuvant eligibility To begin PERJETA and Herceptin® (trastuzumab)-based therapy in the neoadjuvant setting, patients must have HER2+ breast cancer with locally advanced, inflammatory, or early stage breast cancer (either node-positive or tumor size >2 cm).
How effective is PERJETA?
94.1% of the women in the Perjeta treatment group were alive with no cancer recurrence. 93.2% of the women in the standard treatment group were alive with no cancer recurrence.
How is breast cancer staging determined?
Clinical staging is based on the results of tests done before surgery, which may include physical examinations, mammogram, ultrasound, and MRI scans. Pathological staging is based on what is found during surgery to remove breast tissue and lymph nodes. The results are usually available several days after surgery.
Are NCCN Guidelines free?
There is no fee to become a registered user on NCCN.org and to view the NCCN Guidelines.
Will I lose my hair with PERJETA?
Pertuzumab and trastuzumab do not usually cause people to lose their hair. Any hair loss caused by chemotherapy should be temporary and in most cases your hair will begin to grow back once your chemotherapy has ended.
What class of drug is PERJETA?
Drug Type: Pertuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “antineoplastic agent and a monoclonal antibody”.
How long can you stay on Herceptin and PERJETA?
You should receive a total of 1 year (up to 18 cycles) of treatment with PERJETA and Herceptin. This includes any PERJETA and Herceptin you may have been given before surgery. Your treatment may be stopped sooner if your side effects become too difficult to manage or if the cancer comes back.
What does a Category 1 mean in NCCN Guidelines?
The specific definitions of the NCCN categories for recommendations are: • Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate; • Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate; • Category 2B …